Accuracy of iodine density thresholds for the separation of vertebral bone metastases from healthy-appearing trabecular bone in spectral detector computed tomography.
Adult
Aged
Bone Density
Cancellous Bone
/ diagnostic imaging
Female
Humans
Iodine
Iodine Radioisotopes
Lumbar Vertebrae
/ diagnostic imaging
Male
Middle Aged
Multivariate Analysis
Radiographic Image Interpretation, Computer-Assisted
Retrospective Studies
Spinal Neoplasms
/ diagnostic imaging
Tomography, X-Ray Computed
/ methods
Bone
Diagnosis
Iodine
Neoplasm metastasis
Tomography
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
12
04
2018
accepted:
19
10
2018
revised:
14
09
2018
pubmed:
14
12
2018
medline:
25
7
2019
entrez:
8
12
2018
Statut:
ppublish
Résumé
To evaluate quantitative iodine density mapping (IDM) with spectral detector computed tomography (SDCT) as a quantitative biomarker for separation of vertebral trabecular bone metastases (BM) from healthy-appearing trabecular bone (HTB). IRB-approved retrospective single-center-study of portal venous SDCT datasets acquired between June 2016 and March 2017. Inclusion of 43 consecutive cancer patients with BM and 40 without. Target lesions and non-affected control vertebrae were defined using follow-up imaging, MRI, and/or bone scintigraphy. ID and standard deviation were determined with ROI measures by two readers in (a) bone metastases, (b) HTB of BM patients and controls, and (c) ID of various vessels. Volumetric bone mineral density (vBMD) of the lumbar spine and age were recorded. Multivariate ROC analyses und Wilcoxon test were used to determine thresholds for separation of BM and HTB. p < 0.05 was considered significant. ID measurements of 40 target lesions and 83 reference measurements of HTB were acquired. Age (p < 0.0001) and vBMD (p < 0.05) affected ID measurements independently in multivariate models. There were significant differences of ID between metastases (n = 43) and HTB ID (n = 124; mean 5.5 ± 0.9 vs. 3.5 ± 0.9; p < 0.0001), however, with considerable overlap. In univariate analysis, increased ID discriminated bone lesions (AUC 0.90) with a maximum combined specificity/sensitivity of 77.5%/90.7% when applying a threshold of 4.5 mg/ml. Multivariate regression models improved significantly when considering vBMD, the noise of ID, and vertebral venous ID (AUC 0.98). IDM of SDCT yielded a statistical separation of vertebral bone lesions and HTB. Adjustment for confounders such as age and lumbar vBMD as well as for vertebral venous ID and lesion heterogeneity improved discrimination of trabecular lesions. • SDCT iodine density mapping provides the possibility for quantitative analysis of iodine uptake in tissue, which allows to differentiate bone lesions from healthy bone marrow. • Age and vBMD have a significant impact on iodine density measurements. • Iodine density measured in SDCT yielded highest sensitivity and specificity for the statistical differentiation of vertebral trabecular metastases and healthy trabecular bone using an iodine density threshold of 4.5 mg/ml (most performant)-5.0 mg/ml (optimized for specificity).
Identifiants
pubmed: 30523450
doi: 10.1007/s00330-018-5843-y
pii: 10.1007/s00330-018-5843-y
doi:
Substances chimiques
Iodine Radioisotopes
0
Iodine
9679TC07X4
Types de publication
Journal Article
Langues
eng
Pagination
3253-3261Références
Q J Nucl Med. 2001 Mar;45(1):53-64
pubmed: 11456376
Nat Rev Cancer. 2002 Aug;2(8):584-93
pubmed: 12154351
J Bone Miner Res. 2003 Feb;18(2):190-4
pubmed: 12568395
Q J Nucl Med. 2003 Sep;47(3):171-87
pubmed: 12897709
N Engl J Med. 2004 Apr 15;350(16):1655-64
pubmed: 15084698
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
pubmed: 1688381
J Am Acad Orthop Surg. 2006 Oct;14(11):587-98
pubmed: 17030592
J Neuroradiol. 2007 Dec;34(5):311-21
pubmed: 17628678
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Rev Cancer. 2009 Apr;9(4):239-52
pubmed: 19279573
Eur J Radiol. 2011 Sep;79(3):375-81
pubmed: 20223609
Br J Radiol. 1991 May;64(761):409-12
pubmed: 2036562
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Radiographics. 2011 Jul-Aug;31(4):1031-46; discussion 1047-50
pubmed: 21768237
Med Phys. 2012 Nov;39(11):6572-9
pubmed: 23127051
Radiology. 2014 Mar;270(3):825-33
pubmed: 24475821
Eur J Radiol. 2014 Jul;83(7):1216-1221
pubmed: 24820064
Dtsch Arztebl Int. 2014 Oct 31;111(44):741-7
pubmed: 25412631
Eur J Radiol. 2015 May;84(5):901-7
pubmed: 25661696
Radiology. 2015 Sep;276(3):637-53
pubmed: 26302388
Cancer Res. 1989 Dec 1;49(23):6449-65
pubmed: 2684393
Clin Breast Cancer. 2016 Oct;16(5):402-409
pubmed: 27346706
Invest Radiol. 2017 Feb;52(2):288-294
pubmed: 28002240
Eur Radiol. 2017 Sep;27(9):3904-3912
pubmed: 28168368
Invest Radiol. 2017 Aug;52(8):470-476
pubmed: 28422806
Clin Neuroradiol. 2018 Dec;28(4):515-522
pubmed: 28536753
Eur J Radiol. 2017 Aug;93:143-148
pubmed: 28668408
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Radiology. 1980 Dec;137(3):679-86
pubmed: 7003648
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5
pubmed: 7542074